View the NewsRx Library

Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Google 2009 PageRank: #2 Among Top Health News and Media Publications

Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology

Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals

Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This site complies with the HONcode standard for trustworthy health information:
verify here.

Search Results for Keryx Biopharmaceuticals

Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20 Next >

Refine Search

Display Mode: Context | Summary

AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results

2009 NOV 23 ... 3, 2009. The Company's licensee partner for perifosine in North America, Keryx Biopharmaceuticals ("Keryx"), disclosed that it had reached an agreement with the FDA ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

2009 AUG 17 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that it has reached agreement with the U.S. Food and Drug ...

Subject: Myeloma

Price: $3.00

Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements

2009 JUN 29 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that the Company has received a letter from The NASDAQ ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma

2009 SEP 28 ... Keryx Biopharmaceuticals, Inc. announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the ...

Subject: Myeloma

Price: $3.00

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

2009 JUN 22 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced results of the Phase 2 study of Zerenex (ferric citrate) ...

Subject: Renal Disease

Price: $3.00

Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann

2009 AUG 17 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that the Company and Alfa Wassermann S.p.A. have settled a ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals to Present at the Merriman Curhan Ford 6th Annual Investor Summit

2009 NOV 16 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that Ron Bentsur, the Company's Chief Executive Officer, ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

2009 NOV 9 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that Ron Bentsur, the Company's Chief Executive Officer, ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium

2009 SEP 28 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that Phase 2 data of KRX-0401 (perifosine), the Company's ...

Subject: Kidney Cancer

Price: $3.00

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

2009 AUG 17 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results

2009 NOV 23 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego

2009 NOV 9 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that an abstract related to the clinical data of the ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

2009 JUL 27 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced the initiation of a Phase 1 clinical study to evaluate ...

Subject: Solid Cancer

Price: $3.00

Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance

2009 JUN 22 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that on June 5, 2009, it received a letter from the NASDAQ ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Biopharmaceuticals, Inc. to Raise $20 Million in Registered Direct Offering

2009 OCT 12 ... Keryx Biopharmaceuticals, Inc. (the "Company") (NASDAQ:KERX), has entered into definitive agreements to sell 8 ...

Subject: Biopharmaceuticals

Price: $3.00

Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia

2009 OCT 5 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced results of the Open Label Extension (OLE) trial of Zerenex ...

Subject: Clinical Trial Research

Price: $3.00

Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open for Enrollment at Duke Comprehensive Cancer Center

2009 OCT 19 ... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced the initiation of a Phase 2 clinical study to evaluate ...

Subject: Chronic Lymphocytic Leukemia

Price: $3.00

terna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

2009 AUG 17 ... biopharmaceutical company focused on endocrine therapy and oncology, announced that Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), its partner and licensee for perifosine in the North American ...

Subject: Myeloma

Price: $3.00

terna Zentaris Reports Second Quarter 2009 Financial and Operating Results

2009 AUG 24 ... colon cancer and advanced renal cell carcinoma by the Company's partner, Keryx Biopharmaceuticals, Inc. - Acquisition from Ardana Bioscience Ltd. of all assets relating to ...

Subject: Cancer

Price: $3.00

Trade Alerts on Active Stocks: Apple, Keryx, Angiotech, General Mills, Pep Boys and Talbots; Issued by InvestorSoup.com

2009 JUN 22 ... Today's Stock Alerts include: Apple Inc. (NASDAQ:AAPL), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Angiotech Pharmaceuticals Inc. (NASDAQ:ANPI) General Mills Inc. ...

Subject: InvestorSoup.com

Price: $3.00

Results 1 - 20 Next >


Home \| Free Newsletters \| Products \| Article Library \| About Us \| Contact \| Privacy Policy \| Search \| Visit VerticalNews.com Copyright © 2009 NewsRx